Enables BH2 domain binding activity; clathrin binding activity; and identical protein binding activity. Involved in several processes, including mitochondrion organization; positive regulation of cellular component organization; and synaptic vesicle recycling. Located in several cellular components, including Golgi membrane; perinuclear region of cytoplasm; and peroxisome. Is active in presynaptic endocytic zone membrane and synaptic vesicle membrane. Colocalizes with clathrin-coated pit and mitochondrial membrane. Biomarker of chronic kidney disease; dental fluorosis; pulmonary fibrosis; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in encephalopathy due to defective mitochondrial and peroxisomal fission 1 and optic atrophy 5. Orthologous to human DNM1L (dynamin 1 like); PARTICIPATES IN mitochondria fission pathway; endocytosis pathway; Fc gamma receptor mediated signaling pathway; INTERACTS WITH 2,2',4,4'-Tetrabromodiphenyl ether; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1L protein]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1L protein]
4-phenylbutyric acid inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased phosphorylation of DNM1L protein], alpha-Chlorohydrin results in increased expression of and results in increased phosphorylation of DNM1L protein
4-phenylbutyric acid inhibits the reaction [alpha-Chlorohydrin results in increased expression of and affects the localization of DNM1L protein] more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DNM1L mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of DNM1L mRNA, [rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of DNM1L mRNA
4-phenylbutyric acid inhibits the reaction [alpha-Chlorohydrin results in increased expression of and affects the localization of DNM1L protein], 4-phenylbutyric acid inhibits the reaction [alpha-Chlorohydrin results in increased phosphorylation of DNM1L protein]
4-phenylbutyric acid inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased phosphorylation of DNM1L protein]
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of DNM1L mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of DNM1L mRNA
cinnamic acid inhibits the reaction [Glucose results in increased expression of DNM1L protein], Metformin inhibits the reaction [Glucose results in increased expression of DNM1L protein]
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of DNM1L mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of DNM1L mRNA
ATF4 protein promotes the reaction [Arsenic Trioxide affects the expression of DNM1L protein modified form], salvianolic acid A inhibits the reaction [Arsenic Trioxide results in decreased expression of DNM1L protein]
DNM1L protein promotes the reaction [Azides affects the localization of AIFM1 protein], DNM1L protein promotes the reaction [Azides results in increased activity of BAX protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DNM1L mRNA more ...
DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form], DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form]
cinnamic acid inhibits the reaction [Glucose results in increased expression of DNM1L protein], Metformin inhibits the reaction [Glucose results in increased expression of DNM1L protein]
[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA, Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DNM1L mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of DNM1L mRNA, [rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of DNM1L mRNA
ATF4 protein promotes the reaction [Arsenic Trioxide affects the expression of DNM1L protein modified form], salvianolic acid A inhibits the reaction [Arsenic Trioxide results in decreased expression of DNM1L protein]
[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of DNM1L protein, genipin inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of DNM1L protein]
[[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2 more ...
[Fructose co-treated with Palmitic Acid] results in increased expression of DNM1L protein, Fenofibrate inhibits the reaction [[Fructose co-treated with Palmitic Acid] results in increased expression of DNM1L protein]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1L protein]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1L protein]
cinnamic acid inhibits the reaction [Glucose results in increased expression of DNM1L protein], Metformin inhibits the reaction [Glucose results in increased expression of DNM1L protein]
[Fructose co-treated with Palmitic Acid] results in increased expression of DNM1L protein, Fenofibrate inhibits the reaction [[Fructose co-treated with Palmitic Acid] results in increased expression of DNM1L protein]
Homocysteine results in increased expression of and results in increased phosphorylation of DNM1L protein, xestospongin C inhibits the reaction [Homocysteine results in increased expression of and results in increased phosphorylation of DNM1L protein]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1L protein] more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of DNM1L mRNA
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of DNM1L mRNA
mangiferin inhibits the reaction [Methylmercury Compounds results in increased expression of and results in increased phosphorylation of DNM1L protein]
Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of DNM1L protein], Melatonin inhibits the reaction [Doxorubicin results in increased expression of DNM1L protein]
Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA], Melatonin inhibits the reaction [Rotenone results in increased expression of DNM1L protein]
N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]
Acetylcysteine inhibits the reaction [15-deoxyprostaglandin J2 affects the reaction [DNM1L protein binds to DNM1L protein binds to DNM1L protein binds to DNM1L protein]]
Acetylcysteine inhibits the reaction [Diethylhexyl Phthalate affects the localization of DNM1L protein], Acetylcysteine inhibits the reaction [Diethylhexyl Phthalate results in increased expression of and affects the phosphorylation of DNM1L protein]
PQQ Cofactor inhibits the reaction [Rotenone affects the localization of DNM1L protein], PQQ Cofactor inhibits the reaction [Rotenone results in decreased expression of DNM1L mRNA]
resveratrol inhibits the reaction [Rotenone results in decreased expression of DNM1L mRNA], resveratrol inhibits the reaction [Rotenone results in decreased expression of DNM1L protein]
[[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased susceptibility to SB 239063] which results in decreased expression of DNM1L protein
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
